Innox develops botanical drug products aimed at halting the pro-inflammatory cycle that contributes to cancer progression, utilizing FDA guidance for accelerated regulatory pathways. The company addresses the need for effective treatments in oncology by leveraging natural compounds to mitigate inflammation and improve patient outcomes.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer progression is often fueled by a pro-inflammatory cycle, creating a need for effective treatments that can interrupt this process and improve patient outcomes. Current oncology treatments may not adequately address the underlying inflammation contributing to disease advancement.
Solution
Innox develops botanical drug products designed to halt the pro-inflammatory cycle associated with cancer progression. By leveraging natural compounds and adhering to FDA guidance for accelerated regulatory pathways, Innox aims to bring effective treatments to market. The company focuses on mitigating inflammation to improve patient outcomes in oncology.
Target Audience
The primary target audience includes oncology patients and healthcare providers seeking treatments that address inflammation as a contributing factor to cancer progression.
Features
- Development of botanical drug products
- Focus on interrupting the pro-inflammatory cycle in cancer
- Utilization of FDA guidance for accelerated regulatory pathways
- Emphasis on natural compounds for treatment